Add to Favourites
To login click here
Mainz Biomed MYNZ, a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has partnered with Liquid Biosciences to leverage the capabilities of AI in developing an advanced colorectal screening test. The company recently conducted a multi-center international clinical trial in Germany and Norway to evaluate the effectiveness of incorporating mRNA biomarkers into ColoAlert®, their leading product for colorectal cancer (CRC) screening. The study yielded impressive findings, demonstrating a high sensitivity and specificity for detecting CRC and precursor lesions. This partnership has the potential to revolutionize the field of biotechnology and improve healthcare outcomes.
